Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM-300
- Development stage
- Unknown
- Lead developer
- Currax Pharmaceuticals
- Modality
- Small Molecules
01
Overview
CM-300 is an investigational small molecule therapeutic currently in Phase 1 clinical development by Currax Pharmaceuticals for the treatment of obesity. The program is characterized by a polypharmacology approach, suggesting it is designed to interact with multiple biological targets or pathways involved in weight regulation and metabolic health. As of late 2024, the specific molecular targets and chemical structure of CM-300 remain proprietary and have not been publicly disclosed by the sponsor. The asset is part of Currax's early-stage pipeline aimed at expanding its portfolio in the weight management space beyond its established products like Contrave.
Beyond the preview
Go deeper on CM-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM-300.